Real-World Study of Ragweed Sublingual Immunotherapy in Hungary.
| Autor: | Nagy A; Heim Pál National Pediatric Institute, Budapest, Hungary; dr.nagy.adrienne@gmail.com., Balogh K; Buda Allergy Centrum, Budapest, Hungary., Csáki C; Calvinistic Pulmonological Centrum, Törökbálint, Hungary., Fábos B; Kaposi Mór Teaching Hospital, Kaposvár, Hungary., Mohácsi E; St. Janos North-Buda Centrum Hospital, Budapest, Hungary., Papp G; University of Pécs, Szigetvár, Hungary. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Allergologia et immunopathologia [Allergol Immunopathol (Madr)] 2024 Sep 01; Vol. 52 (5), pp. 80-84. Date of Electronic Publication: 2024 Sep 01 (Print Publication: 2024). |
| DOI: | 10.15586/aei.v52i5.1150 |
| Abstrakt: | Background: Ragweed ( Ambrosia elatior ) has become invasive in Europe, causing significant respiratory issues. Subcutaneous allergen immunotherapy (SCIT) has long been used to manage pollen allergies, but sublingual immunotherapy (SLIT) has gained interest. Objective: This study aimed to evaluate the clinical benefits of ragweed SLIT under real-world in a cohort of Hungarian patients allergic to ragweed pollen. Methods: We retrospectively reviewed the clinical records of 57 patients during the 2015 and 2016 ragweed pollen seasons. Patients were divided into two groups: Group 1 (n = 29), who had not received immunotherapy, and Group 2 (n = 28), who had previously undergone immunotherapy with another sublingual preparation. All patients were treated with Oraltek ® ragweed for 4-6 months, initiating 2-4 months before the pollen season and rest of the period was 2 months of the 2016 pollen season. Symptom score (SS), medication score (MS), and combined symptom and medication score (CSMS) were evaluated intra- and intergroup. Results: Pollen counts were consistent between 2015 and 2016. All patients showed significant improvement in SS, MS, and CSMS, with a large effect size (>0.8). Group 2 had significantly lower SS and CSMS in 2015 because of prior immunotherapy. By 2016, both groups exhibited marked improvements, with Group 1 showing a 75% improvement in CSMS. No local or systemic reactions were recorded, indicating a high safety profile. Conclusions: Ragweed SLIT significantly improved symptoms and reduced use of medication in patients allergic to ragweed pollen. The treatment was effective even in patients with previous immunotherapy, with a high benefit-risk ratio demonstrated by the absence of adverse reactions. These findings support the use of Oraltek SLIT for managing ragweed pollen allergy. Competing Interests: The authors declare no potential conflict of interest with respect to research, authorship, and/or publication of this article. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|